CoLucid garners $25M in Series B money

CoLucid Pharmaceuticals says it has rounded up $25 million in Series B financing. New investor Care Capital led the round, which included previous investors Pappas Ventures, Domain Associates, Pearl Street Venture Funds and Triathlon Medical Ventures. The financing will be used to develop COL-144, a migraine compound, and to advance preclinical pipeline candidates that target neurological and psychiatric disorders.

"COL-144 is the first in a new class of migraine therapeutics and represents a paradigm shift in the treatment of migraine," said James White, Ph.D., President and CEO of CoLucid.

- check out CoLucid's release

ALSO: Ibis Biosciences, a unit of Isis Pharmaceuticals, has gained an additional $20 million investment from Abbott Laboratories. Ibis release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.